Imaging Equipment

Photon-Counting CT (NAEOTOM Alpha.Peak)

Photon-counting CT is a modern advancement in computed tomography (CT) that enables particularly precise and high-resolution imaging. Unlike conventional CT systems, this technology directly measures individual X-ray photons and can distinguish their energy. This allows for better differentiation between tumor tissue and benign lesions while simultaneously reducing radiation exposure.

Clinically, photon-counting CT offers particular advantages in oncological imaging, especially in screening, staging, and treatment monitoring. Tumors and metastases can be visualized more precisely, allowing for a more accurate assessment of their extent and response to therapy. Even the smallest lesions can be detected more reliably.

Our research focuses on the quantitative evaluation of image data as well as on AI-supported methods for automated analysis. The goal is to further improve diagnostic information and support personalized treatment decisions.

 

1.5 Tesla MRI (Aera)

The 1.5-Tesla MRI is used for a wide range of oncological applications. Magnetic resonance imaging enables radiation-free and detailed visualization of organs, tissues, and tumors and is particularly suitable for whole-body examinations.

A particular focus is on whole-body MRI, which can be used to assess diseases such as multiple myeloma throughout the entire body. In addition, we perform detailed examinations of the brain, for example to investigate metastases in malignant melanoma. Whole-body screening for genetically determined cancer risks, such as in Li-Fraumeni syndrome, is also part of our clinical and scientific scope.

Other applications include liver examinations for planning and monitoring therapies for liver metastases, as well as the diagnosis of unclear tumor diseases (CUP syndrome), in which the head and neck regions in particular are specifically examined.

 

3 Tesla MRI (Vida, Prisma)

The 3-Tesla MRI offers exceptionally high image resolution and enables detailed visualization of anatomical and functional structures. It is primarily used for specialized diagnostic investigations in oncology.

A key focus is on the examination of brain tumors and metastases, as well as on monitoring treatment during and after radiation therapy. In addition, we use 3-Tesla MRI for early detection in high-risk patients, for example for pancreatic cancer. In close collaboration with the Department of Urology, we perform high-resolution prostate MRI examinations. Additionally, the system enables the visualization of peripheral nerves, for example, to diagnose polyneuropathies.

Our research focuses on the further development of high-resolution MRI techniques as well as on the integration of quantitative and functional imaging into clinical diagnostics.

 

7 Tesla MRI

The 7-Tesla MRI at the DKFZ is an experimental magnetic resonance imaging system with an exceptionally high magnetic field strength. Imaging at 7 Tesla enables a significantly more detailed examination of the human body than conventional MRI systems. This makes it possible to visualize fine anatomical structures and biological processes that are often only partially visible with conventional imaging.

This high-resolution imaging is of particular importance for cancer research. For example, it allows for a more precise examination of differences within individual tumor regions, metabolic activities, or therapeutic effects. The goal is to better characterize tumors and develop new imaging biomarkers for clinical application.

While 7-Tesla MRI systems were originally developed primarily for examinations of the head and extremities, we at the DKFZ are also working on new methods for imaging the trunk, including the spine, as well as organs in the abdominal and pelvic regions.

 

PET-CT and PET-MRI

Positron emission tomography (PET) is a nuclear medicine technique for visualizing biological metabolic processes in the body. For this purpose, a radioactively labeled drug is administered intravenously, and its distribution is then visualized. A radioactively labeled sugar is often used, as many tumors exhibit increased glucose metabolism.

With the help of PET, tumors can be characterized and potential metastases throughout the body can be detected. Tumor types without increased glucose uptake can sometimes be examined using other specific PET tracers.

For precise anatomical localization, PET examinations are combined with computed tomography (PET-CT) or magnetic resonance imaging (PET-MRI). These hybrid procedures allow for the simultaneous acquisition of functional and structural information in a single examination.

Depending on the radiopharmaceutical used, special preparation is required before the examination, such as fasting for examinations with radioactively labeled glucose. After injection, the substance distributes throughout the body within about an hour. The actual examination time is approximately 20 to 90 minutes, depending on the scope of the examination and the system used.